Enliven Therapeutics Inc (ELVN)

Apr 2, 2025, 4:03 PM EDT - 21 days ago

Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

Mar 21, 2025, 6:38 PM EDT - 4 weeks ago

Final Trade: CVX, XLE, ELVN, COF

CVX XLE COF

Mar 13, 2025, 4:05 PM EDT - 5 weeks ago

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Feb 25, 2025, 4:05 PM EST - 2 months ago

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Jan 30, 2025, 7:06 PM EST - 2 months ago

Biotech walks a 'tightrope' amid unclear funding, regulations

DCTH IBB

Jan 7, 2025, 12:28 AM EST - 3 months ago

Enliven's Early Data Stands Out From Peers

Nov 13, 2024, 4:05 PM EST - 5 months ago

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

Nov 7, 2024, 4:05 PM EST - 5 months ago

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference

Oct 18, 2024, 7:18 PM EDT - 6 months ago

Why Enliven is this analyst's top biotech stock pick

Sep 28, 2024, 9:35 AM EDT - 7 months ago

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Sep 18, 2024, 4:05 PM EDT - 7 months ago

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

May 29, 2024, 4:05 PM EDT - 11 months ago

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

May 14, 2024, 4:05 PM EDT - 1 year ago

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Apr 11, 2024, 7:55 AM EDT - 1 year ago

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Apr 9, 2024, 4:05 PM EDT - 1 year ago

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

Mar 19, 2024, 8:30 AM EDT - 1 year ago

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Mar 14, 2024, 4:05 PM EDT - 1 year ago

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Feb 27, 2024, 4:05 PM EST - 1 year ago

Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Aug 18, 2023, 12:57 PM EDT - 1 year ago

Enliven Therapeutics: Preclinical Company With Interesting Value Proposition

Aug 10, 2023, 4:05 PM EDT - 1 year ago

Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Feb 23, 2023, 5:20 PM EST - 2 years ago

Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million

Feb 22, 2023, 4:01 PM EST - 2 years ago

Imara Announces Stockholder Approval of Merger With Enliven

Jan 25, 2023, 1:07 PM EST - 2 years ago

IMARA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Imara Inc. - IMRA

Oct 13, 2022, 4:35 PM EDT - 2 years ago

Enliven Therapeutics and Imara Announce Merger Agreement

Sep 29, 2022, 3:06 PM EDT - 2 years ago

Imara: Potential Liquidation

Apr 5, 2022, 10:13 AM EDT - 3 years ago

Read Why Imara Shares Are Falling Today

Apr 5, 2022, 6:45 AM EDT - 3 years ago

Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

Mar 15, 2022, 11:06 AM EDT - 3 years ago

Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript

Mar 8, 2022, 7:00 AM EST - 3 years ago

Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

Feb 10, 2022, 7:00 AM EST - 3 years ago

Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

Jan 25, 2022, 11:03 AM EST - 3 years ago

Imara To Start Testing Tovinontrine In Heart Failure Patients

Jan 25, 2022, 7:00 AM EST - 3 years ago

Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)

Jan 5, 2022, 7:00 AM EST - 3 years ago

Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

Dec 14, 2021, 7:00 AM EST - 3 years ago

Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021

Nov 22, 2021, 10:36 AM EST - 3 years ago

Imara Changes Primary Endpoint In Mid-Stage Sickle Cell Disease Trial

Nov 22, 2021, 7:00 AM EST - 3 years ago

Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease

Nov 16, 2021, 11:34 AM EST - 3 years ago

Imara's Thalassemia Candidate Shows Reduced Transfusion Burden At Higher Dose

Nov 16, 2021, 7:00 AM EST - 3 years ago

Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dependent Subjects with Beta-thalassemia

Nov 9, 2021, 4:48 PM EST - 3 years ago

IMARA Inc. (IMRA) CEO Rahul Ballal on Q3 2021 Results - Earnings Call Transcript

Nov 9, 2021, 7:00 AM EST - 3 years ago

Imara Reports Third Quarter 2021 Financial Results and Business Highlights

Nov 4, 2021, 4:01 PM EDT - 3 years ago

Imara to Webcast Conference Call of Third Quarter 2021 Financial Results and Business Highlights

Nov 4, 2021, 9:17 AM EDT - 3 years ago

Imara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021

Sep 15, 2021, 7:00 AM EDT - 3 years ago

Imara to Participate in Upcoming Investor Conferences

Sep 3, 2021, 7:00 AM EDT - 3 years ago

Imara to Present at Upcoming Investor Conferences

Aug 8, 2021, 2:44 PM EDT - 4 years ago

IMARA's (IMRA) CEO Rahul Ballal on Q2 2021 Results - Earnings Call Transcript

Aug 6, 2021, 7:00 AM EDT - 4 years ago

Imara Reports Second Quarter 2021 Financial Results and Business Highlights

Aug 5, 2021, 7:15 AM EDT - 4 years ago

Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell Disease